stockrowAligos Therapeutics, Inc.
ALGS Healthcare Biotechnology
Aligos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 million, down 44.6% from fiscal 2024.
- Revenue
- +287.2%
- EPS
- +31.3%
- Free cash flow
- +105.9%
Quarter to September 2026, against a year earlier
Follow ALGS
Alert me
Aligos Therapeutics, Inc. (ALGS) EV/Sales
As of 6 November 2026, Aligos Therapeutics, Inc. (ALGS) trades at a EV/Sales of 0.4×. Over the past ten years it has ranged from −31.9× (April 2025) to 67.8× (January 2022); the current reading is higher than 79% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.5× | (86.61%) |
| FY2024 | 48.8× | — |
| FY2023 | −2.9× | — |
| FY2022 | −6.2× | — |
| FY2021 | 64.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 0.9× | (10.36%) |
| Jun 2026 | 0.9× | (80.02%) |
| Mar 2026 | 4.7× | (27.42%) |
| Dec 2025 | 6.5× | 582.09% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.7× |
| ACET Adicet Bio, Inc. compare | −2.2× |
| IRLA IRulya Therapeutics Inc. compare | n/m |
| ANVS Annovis Bio, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| LITS Lite Strategy, Inc. compare | 0.3× |
| ALGS Aligos Therapeutics, Inc. | 0.4× |
| EDSA Edesa Biotech, Inc. compare | 28.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)